LLLinze Li

Linze Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Linze Li has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CAR-NK cell for gynecological cancers: immune microenvironment remodeling and immunotherapeutic strategies

    by Mingyao Huang, Siyang Wang, Huiyan Huang, Linze Li, Tian Wang

    Gynecological malignancies, including ovarian, cervical, and endometrial cancers, represent a substantial global health burden, contributing significantly to morbidity and mortality among women. Despite advancements in therapeutic strategies, outcomes for many patients remain suboptimal due to challenges such as late-stage detection and resistance to standard treatments. The advent of chimeric antigen receptor (CAR)-engineered natural killer (NK) cells has introduced a cutting-edge immunotherapy option. This review provides an in-depth exploration of the development of CAR-NK cells, emphasizing their sources, design methodologies, and applications in managing gynecological cancers. It also examines current obstacles and outlines innovative strategies to improve the effectiveness and safety of CAR-NK cell-based therapies. Furthermore, we discuss prospective advancements, highlighting the importance of ongoing research and technological innovation to unlock the full potential of CAR-NK cells in the fight against gynecological cancers.


  • Open Access

    Metabolic reprogramming in T cell senescence: a novel strategy for cancer immunotherapy

    by Li Liu, Zhanying Hao, Xi Yang, Yan Li, Siyang Wang, Linze Li

    The complex interplay between cancer progression and immune senescence is critically influenced by metabolic reprogramming in T cells. As T cells age, especially within the tumor microenvironment, they undergo significant metabolic shifts that may hinder their proliferation and functionality. This manuscript reviews how metabolic alterations contribute to T cell senescence in cancer and discusses potential therapeutic strategies aimed at reversing these metabolic changes. We explore interventions such as mitochondrial enhancement, glycolytic inhibition, and lipid metabolism adjustments that could rejuvenate senescent T cells, potentially restoring their efficacy in tumor suppression. This review also focuses on the significance of metabolic interventions in T cells with aging and further explores the future direction of the metabolism-based cancer immunotherapy in senescent T cells.